Leerink Partners analyst Mani Foroohar has maintained their bullish stance on NTLA stock, giving a Buy rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mani Foroohar has given his Buy rating due to a combination of factors surrounding Intellia Therapeutics’ potential and strategic developments. Despite recent safety concerns in their MAGNITUDE studies, the company’s innovative CRISPR-Cas9 therapy, nex-z, remains a significant growth driver in their portfolio. The management’s proactive engagement with regulatory bodies to address safety signals and their strategy to resume trials highlight their commitment to advancing their pipeline.
Additionally, the anticipated launch of lonvo-z for hereditary angioedema is expected to bolster revenue, contributing to the positive outlook. The potential for long-term data from ongoing studies and forthcoming updates at industry conferences further supports the Buy rating, as these developments could enhance investor confidence and provide clarity on the company’s future trajectory.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $25.00 price target.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is neutral on the stock.